menu
    • menu
    [{"orgOrder":0,"company":"EHL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"EHL Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EHL Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EHL Bio \/ Undisclosed"},{"orgOrder":0,"company":"EHL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"EHL Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EHL Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EHL Bio \/ Undisclosed"},{"orgOrder":0,"company":"EHL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Urine-Derived Stem Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"EHL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EHL Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EHL Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by EHL Bio

    Menu

    EHL Bio

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Urine-Derived Stem Cell

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease

                            Details : Autologous Urine-Derived Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 06, 2023

                            Lead Product(s) : Autologous Urine-Derived Stem Cell

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adult Human Mesenchymal Stem Cell

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

                            Details : ADSTEM (Adult Human Mesenchymal Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : ADSTEM

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 24, 2019

                            Lead Product(s) : Adult Human Mesenchymal Stem Cell

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            EHL Bio

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adult Human Mesenchymal Stem Cell

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

                            Details : Adult Human Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 05, 2016

                            Lead Product(s) : Adult Human Mesenchymal Stem Cell

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth